Alto Neuroscience (ANRO) Cash from Investing Activities (2023 - 2026)
Alto Neuroscience (ANRO) reported Cash from Investing Activities of -$556000.0 for Q1 2026, down 2216.67% on a YoY basis from $26267.7 in Q1 2025, and down 2216.67% sequentially from -$24000.0 in Q1 2025.
Alto Neuroscience (ANRO) Cash from Investing Activities (2023 - 2026) Analysis & Trends
Alto Neuroscience (ANRO) has 4 years of Cash from Investing Activities data on file, last reported at -$556000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities fell 2216.67% year-over-year to -$556000.0; the trailing twelve-month figure through Mar 2026 stood at -$556000.0 (up 70.35% YoY), and the FY2025 full-year result was -$24000.0, up 98.84% from the prior year.
- Cash from Investing Activities retreated to -$556000.0 in Q1 2026, from -$24000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of -$21000.0 in Q1 2023 to a low of -$1.0 million in Q3 2024.
- A 4-year average of -$312500.0 and a median of -$282000.0 in 2024 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities slumped 2237.21% in 2024 and surged 89.29% in 2025, its largest moves.
- Tracing ANRO's Cash from Investing Activities over 4 years: stood at -$352000.0 in 2023, then slumped by 43.75% to -$506000.0 in 2024, then surged by 95.26% to -$24000.0 in 2025, then slumped by 2216.67% to -$556000.0 in 2026.
- Business Quant data shows ANRO's Cash from Investing Activities at -$556000.0 in Q1 2026, -$24000.0 in Q1 2025, and -$506000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 172.62 Mn |
| 10 | Alto Neuroscience | 869.36 Mn | 869.36 Mn | - | -556,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -556,000.00 |
| Mar 31, 2026 | -556,000.00 |
| Mar 31, 2025 | -24,000.00 |
| Mar 31, 2025 | -24,000.00 |
| Dec 31, 2024 | -506,000.00 |
| Dec 31, 2024 | -506,000.00 |
| Sep 30, 2024 | -1.01 Mn |
| Sep 30, 2024 | -1.01 Mn |
| Jun 30, 2024 | -340,000.00 |
| Jun 30, 2024 | -340,000.00 |
| Mar 31, 2024 | -224,000.00 |
| Mar 31, 2024 | -224,000.00 |
| Dec 31, 2023 | -352,000.00 |
| Dec 31, 2023 | -352,000.00 |
| Sep 30, 2023 | -43,000.00 |
| Sep 30, 2023 | -43,000.00 |
| Jun 30, 2023 | -54,000.00 |
| Jun 30, 2023 | -54,000.00 |
| Mar 31, 2023 | -21,000.00 |
| Mar 31, 2023 | -21,000.00 |